电与普鲁卡洛普里德对超重慢性便秘的作用:随机对照试验的二次分析
Shuai Gao1, Lili Zhu2, Hao Yao1,3
1Department of Acupuncture, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.
Integrative medicine research
|October 13, 2025
概括
电针 (EA) 与普鲁卡洛普里德治疗超重慢性便秘 (USCC) 的效果相当. 在缓解便秘方面,EA具有相似的疗效,但副作用较少,并且可能具有更持久的效果.
科学领域:
- 胃肠病学 胃肠病学
- 综合医学是一个整体的医学.
- 临床研究 临床研究
背景情况:
- 超严重慢性便秘 (USCC) 的特点是缺乏完全的自发性肠道排便 (CSBM).
- 目前的药理疗法如普鲁卡洛普里德具有局限性和潜在的副作用.
- 探索替代或补充疗法对于管理USCC至关重要.
研究的目的:
- 在USCC患者中,比较电针 (EA) 与普鲁卡洛普里德的疗效和安全性.
- 评估EA对CSBM的影响,排便困难,便一致性和生活质量.
主要方法:
- 一个多中心,非劣势随机对照试验的二次分析.
- 包括317名USCC患者,随机分配给EA或普鲁卡洛普里德.
- 主要结局:平均每周的CSBM (1至8周);次要结局:响应率,症状得分,生活质量,救援药物使用.
主要成果:
- 在从第1至第8周增加每周的CSBM时,EA证明与普鲁卡洛普里德无劣 (P < 0.001).
- 普鲁卡洛普里德在CSBM和便的一致性 (1至2周) 中显示出更快的初步改善.
- 与普鲁卡洛普里德组相比,EA组报告的不良事件显著减少.
结论:
- 电针 (EA) 在治疗USCC时提供了与普鲁卡洛普里德相当的疗效.
- EA具有优越的安全概况,不良事件较少.
- EA可以为便秘症状和生活质量提供持续的好处.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
631
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
631
Drugs for Treatment of Constipation-Predominant IBS
717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
884
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
884


